The 11 analysts offering 12-month price forecasts for Iovance Biotherapeutics Inc have a median target of 45.00, with a high estimate of 60.00 and a low estimate of 35.00. The median estimate represents a +4.68% increase from the last price of 42.99.
The current consensus among 12 polled investment analysts is to Buy stock in Iovance Biotherapeutics Inc. This rating has held steady since November, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.44
Reporting Date Mar 03
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.